Effectiveness of highly active antiretroviral therapy using non-brand name drugs in Brazil
Open Access
- 1 April 2007
- journal article
- research article
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 40 (4) , 551-555
Abstract
In Brazil, HIV-infected individuals receive drugs (including non-brand name drugs which comprise locally produced generics and drugs that have not been tested in bioequivalence trials) free of charge from the government. The objective of the present study was to evaluate the effectiveness of highly active antiretroviral therapy (HAART) in Rio de Janeiro, Brazil, where non-brand drugs are widely used. For this purpose, we estimated the proportion of subjects with virologic failure (plasma HIV viral load greater than 400 copies/mL at 6 months after initiation of treatment). This was a retrospective cohort study of drug-naive HIV-infected subjects who initiated HAART. Subjects were included in the analysis if they were 18 years of age or older, were treatment naive, started HAART with a minimum of 3 drugs, and had available information on blood plasma HIV-1 viral load after 6 months on therapy. All subjects used antiretrovirals in dosing regimens recommended by the Brazilian National Advisory Committee for Antiretroviral Therapy. Chart reviews were conducted in three settings: at two public health outpatient units, at one clinical trial unit and at one private office. No comparisons of the effectiveness of non-brand name with the effectiveness of brand name drugs were made. We present results for 485 patients; of these, 354 (73%), 55 (11%), and 76 (16%) were seen at the public health outpatient units, private office, and clinical trial unit, respectively. Virologic failure was observed in 119 (25%) of the subjects. This study demonstrates the effectiveness of HAART in a setting where non-brand name drugs are widely used.Keywords
This publication has 13 references indexed in Scilit:
- The Changing Natural History of HIV Disease: Before and After the Introduction of Generic Antiretroviral Therapy in Southern IndiaClinical Infectious Diseases, 2005
- Predictors of Virologic Failure in HIV-1-Infected Patients Starting Highly Active Antiretroviral Therapy in Porto Alegre, BrazilJAIDS Journal of Acquired Immune Deficiency Syndromes, 2005
- Patents versus Patients? Antiretroviral Therapy in IndiaNew England Journal of Medicine, 2005
- Efficacy of Antiretroviral Therapy Programs in Resource‐Poor Settings: A Meta‐analysis of the Published LiteratureClinical Infectious Diseases, 2005
- Antiretroviral Therapy in Resource-Poor Countries: Illusions and RealitiesAmerican Journal of Public Health, 2005
- Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patientsAIDS, 2005
- Effectiveness of Antiretroviral Therapy Among Patients Who Attend Public HIV Clinics in Rio de Janeiro, BrazilJAIDS Journal of Acquired Immune Deficiency Syndromes, 2004
- Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trialThe Lancet, 2004
- Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South AfricaAIDS, 2004
- Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studiesThe Lancet, 2003